Moreover, prophylactic vaccination with the HER-2-VLP vaccine reduced spontaneous development of mammary carcinomas by 50–100% in human HER-2 transgenic mice and inhibited the growth of HER-2-positive tumors implanted in wild-type syngeneic mice [129]. This evidence concerns the gene ERBB2 and breast carcinoma.